Skip to content

Our Science

Publications

Journal of Medicinal Chemistry, 2024/12/27

Development and Discovery of a Selective Degrader of Casein Kinases 1δ/ε

Angew. Chem. Int. Ed.; 2023/01/10

Discovery of Potent and Exquisitely Selective Inhibitors of Kinase CK1 with Tunable Isoform Selectivity

Cell Reports Medicine 4, 2023/4/18

A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer

Lancet, 2018/02/21

Chronic lymphocytic leukaemia

Cell, 2018/08/23

Small Molecules Co-targeting CKIα and the Transcriptional Kinases CDK7/9 Control AML in Preclinical Models

Front. Oncol., 2014/05/19

The CK1 family: contribution to cellular stress response and its role in carcinogenesis

Mol Cancer, 2014/10/11

Biological functions of casein kinase 1 isoforms and putative roles in tumorigenesis

Int. J. Mol. Sci., 2020/11/27

Targeting Casein Kinase 1 (CK1) in Hematological Cancers

Med. Res. Rev., 2011/10/12

Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases

Sci. Rep., 2016/07/21

Targeting of the circadian clock via CK1δ/ε to improve glucose homeostasis in obesity

Behav. Pharmacol., 2012/08

An inhibitor of casein kinase 1 ε/δ partially normalizes the manic-like behaviors of the ClockΔ19 mouse

ACS Chem. Neurosci., 2014/10/09

Casein Kinase 1δ/ε Inhibitor PF-5006739 Attenuates Opioid Drug-Seeking Behavior

Blood, 2018/03/15

Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia

4—(1h— imidazol— 5— yl) -1h-pyrrolo [2, 3-b] pyridines for use in the treatment of leukaemias, lymphomas and solid tumors